Literature DB >> 20823688

Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters.

Stephanie Barth1, Peter Klein, Thomas Horbach, Jörg Dötsch, Manfred Rauh, Wolfgang Rascher, Ina Knerr.   

Abstract

OBJECTIVE: We aimed at exploring the expression of neuropeptide Y (NPY), omentin and visfatin in adipose tissues of adults along with clinical parameters and hormones.
METHODS: We included 168 adult patients (31 surgical obese patients and 31 surgical controls, 76 non-surgical obese patients, 30 non-surgical controls). We measured plasma NPY (by radioimmunoassay), cortisol (with an electrochemiluminescence immunoassay) and urinary cortisol metabolites (by gas chromatography/mass spectrometry). Expression of NPY, omentin and visfatin in subcutaneous and visceral adipose tissue specimens of the surgical patients was quantified using real-time PCR.
RESULTS: NPY was detectable in adipose tissue specimens and, like plasma NPY concentrations, comparable between groups. Omentin gene expression was higher in visceral than in subcutaneous adipose tissues (p < 0.0001). Visfatin expression was lower in the subcutaneous tissue of obese patients compared with controls (p < 0.05). Cortisol was lower in obese adults compared with controls (136.5 +/- 74.1 vs. 162.2 +/- 56.1 ng/ml; p < 0.05), cortisol metabolites were comparable between groups.
CONCLUSION: In our obese adults, plasma NPY levels and the glucocorticoid measures were not elevated. Even though the expression of NPY, omentin and visfatin was comparable between obese individuals and controls, we have to consider differences in the total production rate of adipose tissue-derived factors.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823688      PMCID: PMC6452132          DOI: 10.1159/000319508

Source DB:  PubMed          Journal:  Obes Facts        ISSN: 1662-4025            Impact factor:   3.942


  15 in total

1.  Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks.

Authors:  Irena Aldhoon Hainerová; Hana Zamrazilová; Dana Sedláčková; Vojtěch Hainer
Journal:  Obes Facts       Date:  2011-07-28       Impact factor: 3.942

Review 2.  Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy.

Authors:  Shintaro Yamaguchi; Jun Yoshino
Journal:  Bioessays       Date:  2017-03-15       Impact factor: 4.345

Review 3.  Sex dimorphism and depot differences in adipose tissue function.

Authors:  Ursula A White; Yourka D Tchoukalova
Journal:  Biochim Biophys Acta       Date:  2013-05-16

Review 4.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 5.  Physiological and pathophysiological roles of NAMPT and NAD metabolism.

Authors:  Antje Garten; Susanne Schuster; Melanie Penke; Theresa Gorski; Tommaso de Giorgis; Wieland Kiess
Journal:  Nat Rev Endocrinol       Date:  2015-07-28       Impact factor: 43.330

6.  SERUM OMENTIN-1 LEVELS AND ENDOTHELIAL DYSFUNCTION IN OBESITY.

Authors:  A R Çimen; E T Cerit; O T Iyidir; R Karakus; B B Uyar; F B Toruner; N Cakir; M Arslan
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

Review 7.  Inflammation, oxidative stress, and obesity.

Authors:  Alba Fernández-Sánchez; Eduardo Madrigal-Santillán; Mirandeli Bautista; Jaime Esquivel-Soto; Angel Morales-González; Cesar Esquivel-Chirino; Irene Durante-Montiel; Graciela Sánchez-Rivera; Carmen Valadez-Vega; José A Morales-González
Journal:  Int J Mol Sci       Date:  2011-05-13       Impact factor: 5.923

Review 8.  NAD+ homeostasis in human health and disease.

Authors:  Rubén Zapata-Pérez; Ronald J A Wanders; Clara D M van Karnebeek; Riekelt H Houtkooper
Journal:  EMBO Mol Med       Date:  2021-05-27       Impact factor: 12.137

9.  Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day-night variation.

Authors:  Ole-Petter Riksfjord Hamnvik; Bindiya Thakkar; John Chamberland; Konstantinos Aronis; Benjamin Schneider; Christos S Mantzoros
Journal:  Int J Obes (Lond)       Date:  2014-06-20       Impact factor: 5.095

10.  Circulating Omentin-1 Levels Are Decreased in Dilated Cardiomyopathy Patients with Overt Heart Failure.

Authors:  Ying Huang; Yingzhong Lin; Shumin Zhang; Zhijian Wang; Jianwei Zhang; Chao Chang; Ling Liu; Qingwei Ji; Xiaofei Liu
Journal:  Dis Markers       Date:  2016-05-24       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.